27-Oct-2014 - A superbug-fuelled resurgence of polymyxin antibiotics has prompted the European Medicines Agency (EMA) to re-examine safety warnings for the side effect heavy anti-infectives.
News in brief
23-Oct-2014 - Drugmakers’ clashes with regulators over the suitability of API starting materials suggest ICH Q11 is open to interpretation and that clarification is needed according to the EMA.
21-Oct-2014 - Venom from a spider found in a UK household’s shopping basket could treat erectile dysfunction, according to scientists, in one example of drug ingredients being sourced from nature.
20-Oct-2014 - Analysts predicting a second wave of global API hubs say it will be hard for manufacturers in Latin America, Ukraine and Taiwan to avoid the pitfalls that stymied former high growth sectors in Asia.
news from the edqm 50th anniversary conference
15-Oct-2014 - Drug active ingredients in food supplements are Europe’s real falsified medicines problem according to the head of AIFA’s counterfeit prevention team.
News from edqm 50th anniversary conference
14-Oct-2014 - 'Excipient compound' monographs should be included in the European Pharmacopoeia according to IPEC, which argues they would help manufacturers and promote acceptance of the standards outside Europe.
13-Oct-2014 - The auditing company, SGS, recently certified that Capsugel’s manufacturing sites in Colmar, France and Bornem, Belgium meet GMP standards set by EXCiPACT for pharmaceutical excipients manufacturing.
08-Oct-2014 - Despite drizzle and fires at Gare du Nord, the pharmaceutical industry has gathered in Paris France for #CPhIWW. The in-Pharmatechnologist.com team is here to bring you all the latest deals, developments and emerging industry trends.
Ingredients: Featured news
John Giannone - incoming IPEC-Americas chairman
Irwin Silverstein, COO and VP of the International Pharmaceutical Excipients...
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter margins.